EUVIMEDEUVIMED entdecken
Multizentrische Studie

Cisplatin‐ineligible patients with muscle‐invasive bladder cancer demonstrate poor long‐term survival following immediate radical cystectomy

Adnan Fazili iD, Seyed Behzad Jazayeri iD, Kyle M Rose, Christopher Guske, Lexiaochuan Wen, Adri Durant iD, Megan Prunty, Laura Bukavina, Mark D Tyson, G Daniel Grass, Hongzhi Xu, Philippe E Spiess und 7 weitere

BJU International · 2026

DOI: 10.1111/bju.16895 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift BJU International, 2026. Verfasst von Adnan Fazili und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genitourinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Cystectomy, Cisplatin. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To compare survival and oncological outcomes of cisplatin‐ineligible patients (Cis‐I) and cisplatin‐eligible (Cis‐E) patients with muscle‐invasive bladder cancer (MIBC) undergoing immediate radical cystectomy (IRC), as IRC is currently considered the standard‐of‐care for Cis‐I patients with MIBC. Patients and Methods Data from patients with clinical (c)T2–4cN0–1M0 MIBC undergoing IRC, between 2006 and 2021, were retrospectively analysed from four tertiary care centres in the United States. Overall, recurrence‐free and event‐free survival were described using the Kaplan–Meier method and tested using the log‐rank test. For context, we compared survival outcomes against those in Cis‐E patients with MIBC undergoing IRC from the Southwest Oncology Group (SWOG)‐8710 trial.

Results

Overall, 379 Cis‐I and 125 Cis‐E patients with cT2–4cN0–1M0 MIBC who underwent IRC were included. Cis‐I patients included 44.8% cT3/4 vs 60% cT3/4 in the Cis‐E group. Overall, 83.3% of Cis‐I and 79.2% of Cis‐E patients died during follow‐up. The median event‐free and overall survival were 12.1 and 14.5 months for the Cis‐I group and 28.8 and 60.1 months for the Cis‐E group ( P < 0.001). [Correction added on 10 October 2025, after first online publication: The preceding sentence has been revised in this version.] Limitations include retrospective comparison of contemporary multi‐institutional data with that of a randomised control trial.

Conclusions

The Cis‐I patients with MIBC undergoing IRC fared poorly, with a median overall survival of 14.5 (95% confidence interval 11.1–17.9) months, mostly due to non‐cancer‐related deaths. These results provide a benchmark for clinical trials exploring novel agents or alternative chemotherapy regimens in Cis‐I patients with MIBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder NeoplasmsCystectomyCisplatinHumansMaleFemaleRetrospective StudiesAgedMiddle AgedNeoplasm InvasivenessAntineoplastic AgentsAged, 80 and over

Stichwörter der Autor:innen

bladder cancercisplatincystectomyneoadjuvant therapyoutcomes

Substanzen

CisplatinAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Genitourinary Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
  • Department of Urology, Ochsner Medical Center, New Orleans, LA, USA.
  • Department of Urology, Mayo Clinic, Phoenix, AZ, USA.
  • Case Western Reserve University Hospitals, Cleveland, OH, USA.
  • Cleveland Clinic Glickman Urological & Kidney Institute, Cleveland, OH, USA.
  • Department of Radiation Oncology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.

ORCID-Profile: Adnan Fazili, Seyed Behzad Jazayeri, Adri Durant, Roger Li

Zitieren

APA

Fazili, A., Jazayeri, S. B., Rose, K. M., Guske, C., Wen, L., Durant, A., Prunty, M., Bukavina, L., Tyson, M. D., Grass, G. D., Xu, H., Spiess, P. E., Gilbert, S. M., Sexton, W. J., Zemp, L., Pessoa, R. R., Poch, M., Lerner, S. P., & Li, R. (2026). Cisplatin‐ineligible patients with muscle‐invasive bladder cancer demonstrate poor long‐term survival following immediate radical cystectomy. BJU International. https://doi.org/10.1111/bju.16895

Vancouver

Fazili A, Jazayeri SB, Rose KM, Guske C, Wen L, Durant A, et al. Cisplatin‐ineligible patients with muscle‐invasive bladder cancer demonstrate poor long‐term survival following immediate radical cystectomy. BJU International. 2026. doi:10.1111/bju.16895

BibTeX
@article{Fazili2026,
  author = {Fazili, Adnan and Jazayeri, Seyed Behzad and Rose, Kyle M and Guske, Christopher and Wen, Lexiaochuan and Durant, Adri and Prunty, Megan and Bukavina, Laura and Tyson, Mark D and Grass, G Daniel and Xu, Hongzhi and Spiess, Philippe E and Gilbert, Scott M and Sexton, Wade J and Zemp, Logan and Pessoa, Rodrigo Rodrigues and Poch, Michael and Lerner, Seth P and Li, Roger},
  title = {Cisplatin‐ineligible patients with muscle‐invasive bladder cancer demonstrate poor long‐term survival following immediate radical cystectomy},
  journal = {BJU International},
  year = {2026},
  doi = {10.1111/bju.16895}
}
Kostenlos starten →